 Gilead said this week it had allocated nearly all of its supply of the antiviral to the United States over the next three months, stirring concerns about availability elsewhere, particularly in regions where infection rates are still high. I judge us to have adequate stocks, Jonathan Van-Tam, deputy chief medical officer and lead for the Department for Health and Social Care, told a parliamentary hearing. 